Navigation Links
Grifols Breaks Ground on New National Testing Laboratory
Date:10/16/2009

SAN MARCOS, Texas, Oct. 16 /PRNewswire/ -- Today, Grifols S.A. (Grifols), a global healthcare company based in Barcelona, Spain, broke ground on a new national testing laboratory in San Marcos, Texas at a ceremony that included Federal, state and local officials. Construction of the laboratory represents the first phase of a multi-phase expansion that includes additional warehousing and production facilities. When completed, the new facilities will represent a $76 million capital investment and will complement Grifols' existing facilities in Los Angeles, California and Barcelona, Spain.

"San Marcos is proud to help bring the first global healthcare manufacturing facility of this type to the State of Texas," said San Marcos Mayor Susan Narvaiz. "This project represents a significant partnership with Grifols, the City of San Marcos, the State of Texas, and Hays County to create new jobs and a facility that will manufacture life-saving medicines."

"As the mother of a child who uses a plasma medicine and as an advocate for people with primary immunodeficiency diseases, Grifols expansion in San Marcos gives me great comfort that families like mine will have access to life-saving plasma medicines for years to come," said Kathy Antilla, Director of Education for the Immune Deficiency Foundation, the national patient organization for people with primary immunodeficiency (PIDD) diseases. The plasma medicines Grifols produces are used to treat a variety of rare, chronic and often life-threatening diseases such as PIDD, hemophilia and other bleeding disorders, as well as shock, trauma and burns.

"We are pleased to make San Marcos home to our new facilities," said Gregory Rich, President of Grifols, Inc., the company's US division. "Business incentives offered by the City, County and State have helped us realize the goal of preparing for future patient needs of the critically important plasma medicines that we produce." Texas is investing $500,000 in the Grifols expansion project through the Texas Enterprise Fund. The City and County provided substantial incentives to Grifols in the form of property tax relief.

Texas has been an important business hub for Grifols for many years. Currently the state is home to 17 Grifols donor centers and the company's current testing laboratory in Austin. Grifols employs more than 600 Texans and contributes more than $80 million annually to the State's economy through payroll and other business expenses. Plasma and intermediate products are often shipped to the Company's Barcelona facilities through the port of Houston. Construction of the new laboratory, warehousing and production facilities in San Marcos will secure Texas as an essential long-term business home for the company.

About Grifols

Grifols S.A. is a Spain-based company in the healthcare sector involved in the research, development, manufacturing and marketing of plasma therapies, IV therapy solutions, enteral and parenteral nutrition, diagnostic systems, pharmacy automation, and medical materials and devices. Grifols plasma therapies are produced from plasma obtained at 80 donor centers across the US and are used to treat a variety of rare and life-threatening diseases. Founded in 1940, Grifols currently operates in 90 countries with more than 6,000 employees and 26 subsidiaries. Grifols is listed on the Ibex-35 stock market with combined gross revenues over euro 800 million.

For more information about Grifols please visit www.grifols.com.

SOURCE Grifols S.A.


'/>"/>
SOURCE Grifols S.A.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Grifols Breaks Ground on New IVIG Facility
2. Novel Technology Breaks Through Cancer Pain
3. NASA technology helps predict and prevent future pandemic outbreaks
4. Kansas Breaks Into Top 10 in the Nation in Biotech Strength
5. Pennsylvania Governor Rendell Breaks Ground for Global Pharmaceutical Services Companys North American Headquarters
6. A New Way to Predict Outbreaks: Replikin Peptide Concentration in H5N1 Influenza Virus Genome as a Marker for Lethal Outbreaks
7. China Breaks Ground on Largest Comprehensive Stem Cell Storage and Processing Facility
8. Alltech Breaks Through: Named Top Green Company by Inc. Magazine
9. Baxter to Launch GARDian(TM), a Groundbreaking Initiative That Helps Provide Continued Access to GAMMAGARD for Current Patients
10. DuPont, Genencor International and Tate & Lyle Honored for Groundbreaking Work in Developing Bio-PDO(TM)
11. Ground-Breaking Conference Takes on Abortion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/17/2017)... , ... August 17, 2017 , ... ... research and personalized medicine, today announced the launch of a new breast cancer ... The study’s goal is to evaluate the potential for early detection of recurrent ...
(Date:8/16/2017)... ... August 16, 2017 , ... ... a different cell type. Many treatments for specific cancers, such as breast, prostate, ... targeted treatment is androgen deprivation therapy for advanced prostate cancer. , This ...
(Date:8/16/2017)... ... August 16, 2017 , ... ... Food and Drug Administration (FDA) inspection at our Dilworth, MN site. The inspection ... issued. This inspection was conducted as part of a routine Bioresearch Monitoring Program ...
(Date:8/15/2017)... After spending the past two years building a state-of-the-art ... GeneFo now offers this platform to healthcare stakeholders (hospitals, foundations, biopharma ... and data collection vis a vis their members, under their own ... of this offer. ... ...
Breaking Biology Technology:
(Date:4/11/2017)... Research and Markets has announced the addition ... their offering. ... tracking market to grow at a CAGR of 30.37% during the ... 2017-2021, has been prepared based on an in-depth market analysis with ... its growth prospects over the coming years. The report also includes ...
(Date:4/5/2017)... , April 5, 2017  The Allen Institute ... Allen Cell Explorer: a one-of-a-kind portal and dynamic digital ... 3D imaging data, the first application of deep learning ... human stem cell lines and a growing suite of ... platform for these and future publicly available resources created ...
(Date:4/3/2017)... 3, 2017  Data captured by IsoCode, ... detected a statistically significant association between the ... treatment and objective response of cancer patients ... predict whether cancer patients will respond to ... well as to improve both pre-infusion potency testing ...
Breaking Biology News(10 mins):